Pharmacotherapy and growth factors in the treatment of short bowel syndrome.
A review of the pharmacologic substances and growth factors that have been studied experimentally and administered clinically for the management of short bowel syndrome is presented. The medical management of short bowel syndrome is multifaceted. In the acute phase, efforts focus on fluid and electrolyte management and the reduction of gastric acid output. As enteral feeding is initiated, antimotility and antisecretory agents may be effective in reducing gastrointestinal losses. Additional modalities of management, including nutrients and growth factors, may be directed at maximizing absorptive function beyond that which occurs with intestinal adaptation. Continued research aimed at further elucidating the process of intestinal adaptation may allow us to use the various peptides and hormones that act as growth factors for the bowel mucosa. Knowledge gained from these studies combined with gene therapy techniques will result in the permanent enhancement of intestinal function beyond the normal adaptation process, eliminate the dependence on total parenteral nutrition, and avoid the need for intestine transplantation.
Schwartz
M Z
MZ
A.I. duPont Hospital for Children, Wilmington, Delaware 19803, USA.
Kuenzler
K A
KA
D002675:Child, Preschool; D006133:Growth Substances / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007413:Intestinal Mucosa / Q000187:drug effects / Q000503:physiopathology; D007422:Intestines / Q000187:drug effects / Q000503:physiopathology; D012778:Short Bowel Syndrome / Q000188:drug therapy* / Q000503:physiopathology*
D006133:Growth Substances